troglitazone has been researched along with mk 767 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Awano, K; Kinoshita, S; Maeda, T; Miyachi, H; Murakami, K; Nomura, M; Satoh, H; Tsunoda, M | 1 |
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
| Ardecky, R; Broderick, CL; Brooks, DA; Dominianni, SJ; Etgen, GJ; Faul, MM; Karanewsky, DS; Kauffman, RF; McCarthy, JR; Montrose-Rafizadeh, C; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, J; Warshawsky, AM; Winneroski, LL | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Ide, T; Mochizuki, T; Murakami, K; Nakazawa, T | 1 |
| Narce, M; Poisson, JP | 1 |
1 review(s) available for troglitazone and mk 767
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |
5 other study(ies) available for troglitazone and mk 767
| Article | Year |
|---|---|
(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
Topics: Animals; Blood Glucose; Hypoglycemic Agents; Insulin; Mice; Mice, Obese; Pioglitazone; Structure-Activity Relationship; Thiazoles; Thiazolidinediones; Thiazolidines; Triglycerides | 1999 |
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; Hypoglycemic Agents; Mice; Mice, Inbred Strains; Propionates; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Triglycerides | 2001 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
Topics: Administration, Oral; Animals; Chromans; Diabetes Mellitus; Fatty Acids; Hypoglycemic Agents; Liver; Male; Muscle, Skeletal; Obesity; Oxidation-Reduction; Palmitic Acid; Rats; Rats, Zucker; Reference Values; Substrate Specificity; Thiazoles; Thiazolidinediones; Thiazolidines; Triglycerides; Troglitazone | 2000 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |